In advanced malignant melanoma the BRAF V600E mutation can be detected in up to 84% of patients with mutation-positive tumors and the level of mutant DNA (cfBRAFV600E) has been shown to reflect response to targeted treatment including progression and tumor burden [18–20]. The gene discussed is BRAF; the disease is melanoma.